论文部分内容阅读
目的:观察瑞格列奈联用二甲双胍治疗肥胖型2型糖尿病的疗效观察。方法:对100例肥胖型2型糖尿病患者随机分为两组,对照组给予瑞格列奈0.5mg~1mg次/,3次/d,餐前15min服用,观察组50例,在对照组基础上加二甲双胍0.5g次/,3次/d;治疗周期2个月。结果:两组用药后空腹血糖、餐后血糖、糖化血红蛋白明显下降(P>0.05),观察组最显著(P>0.05)。结论:瑞格列奈与二甲双胍片联用治疗肥胖型2型糖尿病具有协同作用,副作用少、依从性好、具有临床应用价值。
Objective: To observe the effect of repaglinide combined with metformin in the treatment of obese type 2 diabetes mellitus. Methods: One hundred cases of obese type 2 diabetes were randomly divided into two groups. The control group was given repaglinide 0.5mg ~ 1mg times / d, 15 minutes before meals and the observation group 50 cases. Add metformin 0.5g times /, 3 times / d; treatment period of 2 months. Results: Fasting blood glucose, postprandial blood glucose and glycosylated hemoglobin were significantly decreased in both groups (P> 0.05). The observation group was the most significant (P> 0.05). Conclusion: The combination of repaglinide and metformin tablets has the synergistic effect in the treatment of obese type 2 diabetes with less side effects and good compliance, and has clinical value.